title: Nesfatin-1 in advanced lung cancer patients with weight loss.
abstract: The cachexia occurs frequently in lung cancer patients. Among appetite regulatory peptides, alteration of expressions of leptin and ghrelin is demonstrated in cachectic cancer patients, but nesfatin-1 has not been yet studied in cancer. We investigated serum nesfatin-1 level in advanced lung cancer patients. Forty-one lung cancer patients and 24 healthy subjects were included to the study. Nesfatin-1 serum levels were analyzed by ELISA kit. Serum nesfatin-1 levels were lower in lung cancer patients than in healthy subjects (0.52±0.19ng/ml vs 0.75±0.23ng/ml; p<0.001). In lung cancer patients with weight loss, nesfatin-1 levels were decreased compared to the patients without weight loss (0.44±0.16ng/ml vs 0.63±0.18ng/ml; p<0.001). Whereas, there were no any difference between patients without weight loss and control subjects (0.63±0.18ng/ml vs 0.75±0.23ng/ml; p:0.129) or between SCLC and NSCLC patients (0.53±0.18ng/ml vs 0.52±0.20ng/ml; p:0.458). No significant correlation was found between serum nesfatin-1 values and BMI. In conclusion, loss of fat mass may decrease serum nesfatin-1 level in lung cancer patients with weight loss. The future studies which explore biological significance of low serum nesfatin-1 level in cancer are needed.
authors.affiliation: Gülhane Military Medical Academy, Department of Nephrology, Turkey.
authors.forename: Hakkı
authors.initials: H
authors.lastname: Cetinkaya
authors.forename: Bülent
authors.initials: B
authors.lastname: Karagöz
authors.forename: Oğuz
authors.initials: O
authors.lastname: Bilgi
authors.forename: Alpaslan
authors.initials: A
authors.lastname: Ozgün
authors.forename: Tolga
authors.initials: T
authors.lastname: Tunçel
authors.forename: Levent
authors.initials: L
authors.lastname: Emirzeoğlu
authors.forename: Cihan
authors.initials: C
authors.lastname: Top
authors.forename: Emin Gökhan
authors.initials: EG
authors.lastname: Kandemir
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015992:Body Mass Index; D002100:Cachexia / Q000097:blood / Q000150:complications / Q000235:genetics* / Q000473:pathology; D002135:Calcium-Binding Proteins / Q000097:blood / Q000235:genetics*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000150:complications / Q000235:genetics* / Q000473:pathology; D016022:Case-Control Studies; D004268:DNA-Binding Proteins / Q000097:blood / Q000235:genetics*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000150:complications / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009419:Nerve Tissue Proteins / Q000097:blood / Q000235:genetics*; D000080866:Nucleobindins; D015431:Weight Loss
chemical_list: D002135:Calcium-Binding Proteins; D004268:DNA-Binding Proteins; C000630650:NUCB2 protein, human; D009419:Nerve Tissue Proteins; D000080866:Nucleobindins